ClinicalTrials.govclosed
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
ClinicalTrials.gov study NCT05845671. IPD Sharing: NO. Countries: 1. Publications: 0.
ShareScore
24/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4
Topics
Dataset details
- Repository
- ClinicalTrials.gov
- Published
- February 11, 2026
- License
- IPD-NO
- DOI
- clinicaltrials.gov/NCT05845671
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.